EMT in breast carcinoma—A review

Journal of Clinical Medicine

Volumn 5, Issue 7, 2016, Pages

  Lima, Joema Felipe ^a,b   Nofech Mozes, Sharon ^b   Bayani, Jane ^a   Bartlett, John M S ^a  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Breast; Cancer; EMT; Invasion; Metastasis

Indexed keywords

ADAMTS1 PROTEIN; BAICALEIN; BETA CATENIN; CLAUDIN; DANUSERTIB; GELATINASE B; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 141; MICRORNA 200B; MICRORNA 200B 3P; MICRORNA 200C; MICRORNA 21; MICRORNA 300; MICRORNA 429; MUCIN 1; NOTCH RECEPTOR; OCCLUDIN; SINOMENINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; INTRADUCTAL CARCINOMA; NONHUMAN; PREDICTIVE VALUE; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; WNT SIGNALING PATHWAY;

EID: 85114283387     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5070065     Document Type: Review

References (54)

1. Prat, A.; Perou, C.M. Desconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011, 5, 5–23.
2. Taube, J.H.; Herschkowitz, J.I.; Komurov, K.; Zhou, A.Y.; Gupta, S.; Yang, J.; Hartwell, K.; Onder, T.T.; Gupta, P.B.; Evans, K.W. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 2010, 107, 15449–15454.
3. Micalizzi, D.; Ford, H. Epithelial to mesenchymal transition in development of cancer. Future Oncol. 2009, 8, 1129–1143.
4. Scimeca, M.; Antonacci, C.; Colombo, D.; Bonfiglio, R.; Buonomo, O.C.; Bonanno, E. Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers. Tumor Biol. 2016, 37, 5427–5435.
5. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. 2009, 9, 265–273.
6. Taylor, M.A.; Parvani, J.G.; Schiemann, W.P. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-β in normal and malignant mammary epithelial cells. J. Mammary Gland Biol. Neoplasia 2010, 15, 169–190.
7. Sarrió, D.; Rodriguez-Pinilla, S.M.; Hardisson, D.; Cano, A.; Moreno-Bueno, G.; Palacios, J. Epithelial-Mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008, 68, 989–997.
8. Lien, H.C.; Hsiao, Y.H.; Lin, Y.S.; Yao, Y.T.; Juan, H.F.; Kuo, W.H.; Hung, M.C.; Chang, K.J.; Hsieh, F.J. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: Identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007, 26, 7859–7871.
9. Al Saleh, S.; Al Mulla, F.; Luqmani, Y.A. Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS ONE 2011, 6, e20610.
10. Pomp, V.; Leo, C.; Mauracher, A.; Korol, D.; Guo, W.; Varga, Z. Differential expression of epithelial-mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. Breast Cancer Res. Treat. 2015, 154, 45–55.
11. Czerwinska, P.; Kaminska, B. Regulation of breast cancer stem cell features. Contemp. Oncol. 2015, 19, A7–A15.
12. Coradini, D.; Boracchi, P.; Ambrogi, F.; Biganzoli, E.; Oriana, S. Cell polarity. Epithelial-mesenchymal transition and cell-fate decision gene expression in ductal carcinoma in situ. Int. J. Surg. Oncol. 2012, 2012, 984346.
13. Wang, Y.; Zhou, B.P. Epithelial-mesenchymal transition—A hallmark of breast cancer metastasis. Cancer Hallm. 2013, 1, 38–49.
14. Knudsen, E.S.; Ertel, A.; Davicioni, E.; Kline, J.; Schwartz, G.F.; Witkiewicz, A.K. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelial. Breast Cancer Res. Treat. 2012, 133, 1009–1024.
15. Bouris, P.; Skandalis, S.S.; Piperigkou, Z.; Afratis, N.; Karamanou, K.; Aletras, A.J.; Moustakas, A.; Theocharis, A.D.; Karamanos, N.K. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015, 43, 42–60.
16. Radisky, E.; Radisky, D. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 2012, 15, 201–212.
17. Cichon, M.A.; Nelson, C.M.; Radisky, D.C. Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion. Cancer Inform. 2015, 14 (Suppl. 3), 1–13.
18. Faronato, M.; Nguyen, V.T.; Patten, D.K.; Lombardo, Y.; Steel, J.H.; Patel, N.; Woodley, L.; Shousha, S.; Pruneri, G.; Coombes, R.C. et al. DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation. Oncotarget 2015, 6, 22467–22479.
19. Fischer, K.; Durrans, A.; Lee, S.; Sheng, J.; Li, F.; Wong, S.T.; Choi, H.; El Rayes, T.; Ryu, S.; Troeger, J. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015, 527, 472–476.
20. Lombaerts, M.; van Wezel, T.; Philippo, K.; Dierssen, J.W.; Zimmerman, R.M.; Oosting, J.; van Eijk, R.; Eilers, P.H.; van de Water, B.; Cornelisse, C.J. et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 2006, 94, 661–671.
21. Ciriello, G.; Gatza, M.L.; Beck, A.H.; Wilkerson, M.D.; Rhie, S.K.; Pastore, A.; Zhang, H.; McLellan, M.; Yau, C.; Kandoth, C.; et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015, 163, 506–519.
22. Onder, T.T.; Gupta, P.B.; Mani, S.A.; Yang, J.; Lander, E.S.; Weinberg, R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68, 3645–3654.
23. Thomson, S.; Petti, F.; Sujka-Kwok, I.; Mercado, P.; Bean, J.; Monaghan, M.; Seymour, S.L.; Argast, G.M.; Epstein, D.M.; Haley, J.D. A system view of epithelial-mesenchymal transition signaling states. Clin. Exp. Metastasis 2011, 28, 137–155.
24. Abdulla, T.; Luna-Zurita, L.; de la Pompa, J.L.; Schleich, J.M.; Summers, R. Epithelial to mesenchymal transition—The roles of cell morphology, labile adhesion and junctional coupling. Comput Methods Progr. Biomed. 2013.
25. Katz, E.; Dubois-Marshall, S.; Sims, A.H.; Gautier, P.; Caldwell, H.; Meehan, R.R.; Harrison, D.J. An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer. PLoS ONE 2001, 6, e17083.
26. Nelson, W.J.; Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303, 1483–1487.
27. Geyer, F.C.; Lacroix-Triki, M.; Savage, K.; Arnedos, M.; Lambros, M.B.; MacKay, A.; Natrajan, R.; Reis-Filho, J.S. β-catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod. Pathol. 2011, 24, 209–231.
28. Mukherjee, N.; Panda, C. Subtype-specific alterations of the Wnt signaling pathway in breast cancer. Clin. Progn. Signif. Cancer Sci. 2012, 103, 210–220.
29. Li, Y.; Wang, Z. Regulation of EMT by Notch signaling pathway in tumor progression. Curr. Cancer Drug Targets 2013, 13, 957–962.
30. Farnie, G.; Clarke, R. Mammary stem cells and breast cancer—Role of Notch signaling. Stem Cell Rev. 2007, 3, 169–175.
31. Yuan, X.; Zhang, M.; Wu, H.; Xu, H.; Han, N.; Chu, Q.; Yu, S.; Chen, Y.; Wu, K. Expression of Notch 1 correlates with breast cancer progression and prognosis. PLoS ONE 2015, 10, e0131689.
32. Liu, Z.J.; Semenza, G.L.; Zhang, H.F. Hypoxia-inducible factor 1 and breast cancer metastasis. Biomed. Biotechnol. 2015, 16, 32–43.
33. Aiwei, Y.; Kieber-Emons, T. Adipocyte hypoxia causes epithelial to mesenchymal transition—Related gene expression and estrogen receptor-negative phenotype in breast cancer cells. Oncol. Rep. 2015, 33, 2689–2694.
34. Ho, M.Y.; Tang, S.J.; Chuang, M.J.; Cha, T.L.; Li, J.Y.; Sun, G.H.; Sun, K.H. TNF- induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism. Mol. Cancer Res. 2012, 10, 1109–1119.
35. Li, C.W.; Xia, W.; Huo, L.; Lim, S.O.; Wu, Y.; Hsu, J.L.; Chao, C.H.; Yamaguchi, H.; Yang, N.K.; Ding, Q. et al. Epithelial-mesenchymal transition induced by TNF- requires NF-B-mediated transcriptional upregulation of Twist 1. Cancer Res. 2012, 72, 1290–1300.
36. Iorio, M.; Ferracin, M.; Liu, C.G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065–7070.
37. Rhodes, L.V.; Martin, E.C.; Segar, H.C.; Miller, D.F.; Buechlein, A.; Rusch, D.B.; Nephew, K.P.; Burow, M.E.; Collins-Burow, B.M. Dual regulation by micro RNA-200b-3b and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget 2015, 6, 16639–16652.
38. Creighton, C.J.; Gibbons, D.L.; Kurie, J.M. The role of epithelial-mesenchymal transition programming in invasion and metastasis: A clinical perspective. Cancer Manag. Res. 2013, 5, 187–195.
39. Guttilla, I.; White, B. ER, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol. Metab. 2012, 3, 73–82.
40. Yu, J.; Xie, F.; Bao, X.; Chen, W.; Xu, Q. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer. Mol. Cancer 2014, 13, 121.
41. Lin, Y.; Dong, C.; Zhou, B.P. Epigenetic regulation of EMT: The snail story. Curr. Pharm. Des. 2014, 20, 1698–1705.
42. Sigurdsson, V.; Gudjonsson, T. Endothelial induced EMT in breast epithelial cells with stem cells properties. PLoS ONE 2011, 6, e23833.
43. Wendt, M.K.; Schiemann, W.P. Mechanisms of epithelial-mesenchymal transition by TGF-β. Future Oncol. 2009, 5, 1145–1168.
44. Kalluri, R.; Wienberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428.
45. Groger, C.; Grubinger, M.; Waldhör, T.; Vierlinger, K.; Mikulits, W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS ONE 2012, 7, e51136.
46. Srishti, K.; Susinjam, B. Breast cancer stem cells, EMT and therapeutic targets. Biochem. Biophys. Res. Commun. 2014, 453, 112–116.
47. Eaves, C. Cancer stem cells: Here, there, everywhere? Nature 2008, 456, 581–582.
48. Alkatout, I.; Klapper, W. Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor center and margin of invasive breast cancer. Exp. Mol. Pathol. 2013, 94, 168–173.
49. Li, J.P.; Yang, Y.X.; Liu, Q.L.; Zhou, Z.W.; Pan, S.T.; He, Z.X.; Zhang, X.; Yang, T.; Pan, S.Y.; Duan,W.; et al. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells. Drug Des. Dev. Ther. 2015, 9, 1027–1062.
50. Yen, W.C.; Fischer, M.M.; Axelrod, F.; Bond, C.; Cain, J.; Cancilla, B.; Henner, W.R.; Meisner, R.; Sato, A.; Shah, J. et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (Tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin. Cancer Res. 2015, 21, 2084–2094.
51. Lin, L.; Mernaugh, R.; Yi, F.; Blum, D.; Carbone, D.P.; Dang, T.P. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res. 2010, 70, 632–638.
52. Song, L.; Liu, D.; Zhao, Y.; He, J.; Kang, H.; Dai, Z.; Wang, X.; Zhang, S.; Zan, Y. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-B activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem. Biophys. Res. Commun. 2015, 464, 705–710.
53. Ma, X.; Yan, W.; Dai, Z.; Gao, X.; Ma, Y.; Xu, Q.; Jiang, J.; Zhang, S. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway. Drugs Des. Dev. Ther. 2016.
54. Han, M.; Liu, M.; Wang, Y.; Chen, X.; Xu, J.; Sun, Y.; Zhao, L.; Qu, H.; Fan, Y.; Wu, C. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS ONE 2012, 7, e39520.